| A review of cancer immunotherapy: from the past, to the present, to the future K Esfahani, L Roudaia, N Buhlaiga, SV Del Rincon, N Papneja, WH Miller Current Oncology 27 (s2), 87-97, 2020 | 839 | 2020 |
| Moving towards personalized treatments of immune-related adverse events K Esfahani, A Elkrief, C Calabrese, R Lapointe, M Hudson, B Routy, ... Nature reviews Clinical oncology 17 (8), 504-515, 2020 | 227 | 2020 |
| Alemtuzumab for immune-related myocarditis due to PD-1 therapy K Esfahani, N Buhlaiga, P Thébault, R Lapointe, NA Johnson, ... New England Journal of Medicine 380 (24), 2375-2376, 2019 | 196 | 2019 |
| Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade K Esfahani, WH Miller Jr New England Journal of Medicine 376 (20), 1989-1991, 2017 | 184 | 2017 |
| Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation K Esfahani, TA Al-Aubodah, P Thebault, R Lapointe, M Hudson, ... Nature communications 10 (1), 4712, 2019 | 93 | 2019 |
| Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial B Routy, JG Lenehan, WH Miller Jr, R Jamal, M Messaoudene, ... Nature medicine 29 (8), 2121-2132, 2023 | 86 | 2023 |
| Tofacitinib for refractory immune-related colitis from PD-1 therapy K Esfahani, M Hudson, G Batist New England Journal of Medicine 382 (24), 2374-2375, 2020 | 66 | 2020 |
| Endocrine therapy for breast cancer in the primary care setting A Awan, K Esfahani Current Oncology 25 (4), 285-291, 2018 | 64 | 2018 |
| Adverse events associated with immune checkpoint inhibitor treatment for cancer K Esfahani, N Meti, WH Miller, M Hudson Cmaj 191 (2), E40-E46, 2019 | 45 | 2019 |
| The role of immune checkpoint inhibitors in classical Hodgkin lymphoma N Meti, K Esfahani, NA Johnson Cancers 10 (6), 204, 2018 | 43 | 2018 |
| HSP90 as a novel molecular target in non-small-cell lung cancer K Esfahani, V Cohen Lung Cancer: Targets and Therapy, 11-17, 2016 | 33 | 2016 |
| A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer K Esfahani, JS Agulnik, V Cohen Frontiers in Oncology 4, 174, 2014 | 32 | 2014 |
| Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials K Esfahani, A Aspler, D Menzies, K Schwartzman The International journal of tuberculosis and lung disease 15 (10), 1340-1346, 2011 | 17 | 2011 |
| Phase I/II trial of sorafenib in combination with vinorelbine as first-line chemotherapy for metastatic breast cancer C Ferrario, I Strepponi, K Esfahani, H Charamis, A Langleben, E Scarpi, ... PLoS One 11 (12), e0167906, 2016 | 15 | 2016 |
| Refractory neutropenia secondary to dual immune checkpoint inhibitors that required second-line immunosuppression N Meti, T Petrogiannis-Haliotis, K Esfahani J Oncol Pract 14 (8), 514-516, 2018 | 13 | 2018 |
| Acute liver failure because of chronic lymphocytic leukemia: case report and review of the literature K Esfahani, P Gold, S Wakil, RP Michel, S Solymoss Current oncology 18 (1), 39-42, 2011 | 13 | 2011 |
| Fecal microbiota transplantation followed by anti–PD-1 treatment in patients with advanced melanoma. WH Miller, B Routy, R Jamal, DS Ernst, D Logan, K Esfahani, K Belanger, ... Journal of Clinical Oncology 40 (16_suppl), 9533-9533, 2022 | 10 | 2022 |
| A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. QS Chu, DJ Jonker, DM Provencher, WH Miller, N Bouganim, AF Shields, ... Journal of Clinical Oncology 38 (15_suppl), 3581-3581, 2020 | 10 | 2020 |
| Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy MM Almajed, K Esfahani, M Pelmus, L Panasci Case Reports 2016, bcr2016215525, 2016 | 9 | 2016 |
| A phase I open prospective cohort trial of curcumin plus tyrosine kinase inhibitors for EGFR-mutant advanced non-small cell lung cancer. K Esfahani, L Boodaghians, G Kasymjanova, JS Agulnik, C Pepe, L Sakr, ... Journal of Clinical Oncology 37 (15_suppl), e20611-e20611, 2019 | 8 | 2019 |
